Pirlimycin for Cow: Uses, Dosing & Side Effects

This information is for educational purposes only. Never give your pet any medication without your veterinarian's guidance. Dosing, frequency, and safety depend on your pet's specific health profile.

Pirlimycin is a prescription lincosamide antibiotic used in cattle as an intramammary infusion, meaning it is placed directly into the affected udder quarter under your vet's guidance. In the US, pirlimycin is approved for use in lactating dairy cattle and is commonly sold under the brand name Pirsue. It works by binding to the bacterial 50S ribosomal subunit and interfering with protein synthesis, which helps control susceptible bacteria.

Pirlimycin is mainly active against gram-positive mastitis pathogens. That matters because it is a targeted option for some mastitis cases, but not all of them. It is not a good choice for gram-negative organisms such as E. coli, so culture results, herd history, milk appearance, and the cow's overall condition all help your vet decide whether it fits the case.

Because this is a food-animal medication, correct use is especially important. Your vet will consider milk discard time, meat withdrawal time, the number of quarters affected, and whether the cow has mild disease or a more serious infection needing additional treatment.

Pirlimycin is labeled for the treatment of clinical and subclinical mastitis in lactating dairy cows caused by susceptible bacteria, especially Staphylococcus aureus, Streptococcus agalactiae, Streptococcus dysgalactiae, and Streptococcus uberis. These are common gram-positive mastitis pathogens, and pirlimycin is one of the intramammary options your vet may choose when the case pattern supports that type of infection.

It is usually considered when the cow has mild to moderate udder disease, such as abnormal milk, mild udder swelling, or elevated somatic cell count without severe whole-body illness. In chronic Staph. aureus cases, pirlimycin may help control infection, but cure rates can be less predictable. That is one reason your vet may recommend milk culture, follow-up testing, or a broader herd-level mastitis plan.

Pirlimycin alone is not enough for every mastitis case. If a cow has acute or peracute mastitis, marked udder damage, dehydration, fever, depression, or other systemic signs, your vet may pair intramammary treatment with supportive care, anti-inflammatory medication, fluids, or systemic antibiotics depending on the situation.

Pirlimycin dosing in cows should always follow your vet's instructions and the product label. The labeled US regimen for pirlimycin intramammary solution is one syringe into each affected quarter, then repeat in 24 hours. Each syringe contains 50 mg pirlimycin hydrochloride. In some cases, labeled daily treatment may be continued every 24 hours for up to 8 consecutive days, but longer treatment changes meat withdrawal timing and should only be done under veterinary direction.

Good technique matters. The teat end should be cleaned carefully, and the medication should be infused using proper intramammary sanitation to reduce the risk of introducing new bacteria. If technique is poor, repeated treatment can increase the chance of environmental mastitis, including infections caused by organisms that pirlimycin does not treat well.

Withdrawal times are a major part of dosing decisions in dairy cattle. Milk from treated cows must be discarded during treatment and for 36 hours after the last treatment. After the standard 2-dose regimen given 24 hours apart, the labeled pre-slaughter withdrawal is 9 days. If therapy is extended beyond the 2-dose course and continued up to 8 days, the pre-slaughter withdrawal increases to 21 days. Your vet can help you document these dates clearly for milk and meat safety.

Pirlimycin is generally well tolerated when used as labeled, but side effects and treatment complications can still happen. The most important practical concern is that repeated intramammary infusion, especially with extended-duration therapy, can increase the risk of new intramammary infection from environmental bacteria if teat preparation and infusion technique are not meticulous.

Some cows may have persistent abnormal milk, elevated somatic cell counts, or ongoing mastitis signs if the infecting organism is not susceptible, if the infection is chronic, or if there is deeper udder damage. In those cases, the issue may look like a medication side effect when it is really treatment failure or a new infection. Your vet may recommend culture, recheck milk samples, or a different treatment plan.

See your vet immediately if the cow develops fever, depression, reduced appetite, dehydration, severe udder swelling, watery or bloody milk, weakness, or rapid worsening after treatment starts. Those signs can point to severe mastitis or a pathogen that needs a different approach. Also contact your vet right away if there is any concern about accidental residue risk from missed milk discard or withdrawal timing.

Pirlimycin belongs to the lincosamide class. Drugs in this class share ribosomal binding sites with macrolides, streptogramins, and phenicols, so there is potential for overlapping activity patterns and cross-resistance concerns. In practice, that means your vet may think carefully before combining pirlimycin with other antibiotics that work at similar ribosomal sites, especially if culture and susceptibility information are limited.

For mastitis cases, the bigger issue is often not a classic drug-drug interaction but a treatment-plan interaction. For example, using pirlimycin in a cow with severe toxic mastitis may delay more appropriate supportive care if the case really needs fluids, anti-inflammatory treatment, systemic therapy, or a different intramammary drug. Your vet will also consider milk and meat withdrawal implications if multiple medications are used together or if any drug is used extra-label.

Tell your vet about all medications, intramammary tubes, anti-inflammatory drugs, supplements, and recent treatments the cow has received. That helps your vet avoid residue problems, duplicate antibiotic coverage, and combinations that may complicate interpretation of treatment response.